Brought to you by 
Elan grants Acorda US rights to its Zanaflex
28 Jul 2011
Executive Summary
Acorda Therapeutics (drugs for nervous system disorders) received exclusive US rights to sell, market, and distribute Elan Pharmaceuticals' Zanaflex (tizanidine) tablet formulation, which is indicated for the management of spasticity.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elan grants Acorda US rights to its Zanaflex
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice